MDAI

Over the past six months, Spectral AI's stock has been impacted by several events. The company received $31.7 million in BARDA funding, causing shares to surge by 35%. Vincent S. Capone was appointed as CEO. MDAI reported earnings of $0.02 per share, surprising estimates by 115.79%, but R&D revenue dropped 50% due to reduced BARDA contract reimbursements. The company submitted the DeepView® System to the FDA for market authorization, with approval expected by the end of Q2 2026. Analysts have a bullish consensus with a median price target of $5.00. The stock price has seen significant movement, with a 50% jump in the last month and a 92.17% increase over the past year.